This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more
Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and investment is back on the...more
Consumer brands are emerging to serve unmet needs in everything from health and wellness to sustainability. Josh Beser and Samir Bakhru were fortunate to meet many of these new companies and investors at the Consensus Great...more